Supporting Information

(Salen)Mn(III)-Catalyzed Chemoselective Acylazidation of Olefins

Liang Zhang, Shuya Liu, Zhiguo Zhao, Hongmei Su, Jingcheng Hao, and Yao Wang*

School of Chemistry and Chemical Engineering, Key Laboratory of the Colloid and Interface Chemistry, Ministry of Education, Shandong University, Jinan 250100, China

Email: yaowang@sdu.edu.cn

Table of Contents:

1. General information	S2
2. Preparation of substrates and catalysts	S2-S3
3. General procedure for acylazidation of olefinic compounds	S3
4. Analytical data	S4-S12
5. Mechanistic study	S12-S15
6. X-ray crystallographic data	S16
7. Copies of NMR spectra	
8. HPLC trace of 3a and 3d	
9. References.	S65

1. General Information

All the chemicals were either purchased from commercial suppliers or purified by standard procedures as specified in *Purification of Laboratory Chemicals*, 4th Ed (Armarego, W. L. F.; Perrin, D. D. Butterworth Heinemann: 1997). All reactions were carried out under nitrogen atmosphere. Optically pure catalyst **C7** was purchased from Sigma-Aldrich: product number 404446, CAS Number: 138124-32-0. Analytical thin-layer chromatography (TLC) was performed on silica gel plates and analyzed by UV light or by potassium permanganate stains followed by heating. Flash chromatography was carried out utilizing silica gel (200-300 mesh). ¹H NMR, ¹³C NMR spectra were recorded in CDCl₃ at room temperature on a Bruker AM-400 spectrometer (400MHz ¹H, 100MHz ¹³C). The chemical shifts are reported in ppm relative to either the residual solvent peak (¹³C) (δ = 77 ppm) or TMS (¹H) (δ = 0 ppm) as an internal standard. Data for ¹H NMR are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, dd = doublet doublet), coupling constant (Hz), integration. Data for ¹³C NMR are reported as chemical shift. HRMS were performed on a Bruker Apex II mass instrument (ESI).

2. Preparation of the substrates and catalysts

The substrates **1q**, **1s** were prepared according to the literature procedure as reported by Liwosz.^[1] The substrates **1aa–1an** were prepared according to the literature procedure.^[2-4] The substrate vinylestrone **4a'** was prepared according to the literature procedure.^[5-6] The substrate **1u** was prepared according to the literature procedure.^[7] (salen)Mn(III) complexes were prepared according to the literature procedure.^[8-9]

The substrates **4b'**, **5a'**, and **5b'** were prepared according to the similar methods as reported by literature procedure.^[10-11]



The preparation of 4b':

N-(3-dimethylaminopropyl)-*N*²-ethylcarbodiimide hydrochloride (920.0 mg, 4.8 mmol, 1.20 equiv) was added to a suspension of (*S*)-1-cinnamoylpyrrolidine-2-carboxylic acid (981.0 mg, 4.0 mmol, 1.0 equiv), estrone (1081.0 mg, 4.0 mmol, 1.0 equiv), and 4-dimethylaminopyridine (147.0 mg, 1.2 mmol, 0.3 equiv) in dry CH₂Cl₂ (40.0 mL), and then the reaction mixture was stirred at 23 °C for 15 h . The reaction mixture was then concentrated in vacuum and the residue was purified by chromatography on silica gel, eluting with CH₂Cl₂:CH₃OH (400:1 to 100:1 (v/v)), to afford **4b'** as a white solid (1295.0 mg, 2.6 mmol, 65% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, *J* = 15.5 Hz, 1H), 7.50-7.61 (m, 2H), 7.34-7.43 (m, 3H), 7.24-7.30 (m, 1H), 6.85-6.99 (m, 2H), 6.78 (d, *J* = 15.5 Hz, 1H), 4.81 (dd, *J* = 3.9, 8.4 Hz, 1H), 3.87-3.96 (m, 1H), 3.74-3.82 (m, 1H), 2.85-3.03 (m, 2H), 2.46-2.56 (m, 1H), 2.34-2.49 (m, 2H), 2.18-2.33 (m, 3H), 1.93-2.61 (m, 5H), 1.38-1.66 (m, 6H), 0.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 220.7, 171.1, 165.0, 148.6, 142.9, 137.9, 137.3, 135.1, 129.8, 128.8, 127.9, 126.2, 121.5, 118.6, 117.9, 59.3, 50.4, 47.9, 47.0, 44.1, 38.0, 35.8, 31.5, 29.3, 29.2, 26.3, 25.7, 25.0, 21.5, 13.8; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₃₂H₃₆NO₄) requires m/z 498.2644, found m/z 498.2645.

The preparation of the 5a' and 5b':

To a stirring solution of (S)-1-cinnamoylpyrrolidine-2-carboxylic acid (1230.0 mg, 5.0 mmol) and triethylamine

(690.0 uL, 5.0 mmol) in THF (7.5 mL) was added isobutylchloroformate (630.0 uL, 5.0 mmol) at -10 °C. After vigorous stirring for 50-60s, a solution of *L*-valine methyl ester hydrochloride (920.0 mg, 5.5 mmol) in DMSO (0.25 mL) was added followed by a solution of triethylamine (1.55 mL, 11.0 mmol) in THF (15.0 mL). The reaction mixture was then warmed to room temperature and vigorously stirred for 4.0 h. After the completion of the reaction, triethylamine hydrochloride was filtered off. The filtrate was concentrated and the residue was dissolved in EtOAc (30.0 mL). The solution was washed with saturated aqueous NaHCO₃ (2×10.0 mL), and brine (1×10.0 mL), then dried over Na₂SO₄, filtered, and evaporated under reduced pressure to afford the crude product, which was further purified by column chromatography CH₂Cl₂:CH₃OH (500:1 to 100:3 (v/v)) to yield **5a'** in 55% yield (1092.0 mg, 55%). ¹H NMR (400 MHz, CDCl₃): δ 7.80 (d, *J* = 8.0 Hz, 1H), 7.77 (d, *J* = 15.4 Hz, 1H), 7.51-7.58 (m, 2H), 7.35-7.41 (m, 3H), 6.77 (d, *J* = 15.4 Hz, 1H), 4.81 (d, *J* = 7.2 Hz, 1H), 4.44 (dd, *J* = 5.1, 8.3 Hz, 1H), 3.76-3.81 (m, 1H), 3.74 (s, 3H), 3.61-3.69 (m, 1H), 2.45-2.53 (m, 1H), 2.13-2.23 (m, 2H), 1.99-2.10 (m, 1H), 1.80-1.92 (m, 1H), 0.91 (d, *J* = 6.8 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 172.2, 171.1, 166.2, 143.3, 134.9, 130.0, 128.8, 128.0, 117.8, 59.8, 57.6, 52.0, 47.4, 30.9, 26.8, 25.1, 19.1, 17.7; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₀H₂₇N₂O₄) requires m/z 359.1971, found m/z 359.1964.

To a stirring solution of (*S*)-1-cinnamoylpyrrolidine-2-carboxylic acid (615.3 mg, 2.5 mmol) and triethylamine (346.5 uL, 2.5 mmol) in THF (3.8 mL) was added isobutylchloroformate (315.5 uL, 2.5 mmol) at -10 °C. After vigorous stirring for 50-60s, a solution of *L*-Phenylalanine methyl ester (448.0 uL, 2.75mmol) in THF (0.5 mL) was added dropwise. The reaction mixture was then warmed to room temperature and vigorously stirred for 4.0 h. After the completion of the reaction, the mixture was concentrated and the residue was dissolved in EtOAc (30.0 mL). The solution was washed with water (2×10.0 mL), and brine (1×10.0 mL), then dried over Na ₂SO₄, filtered, and evaporated under reduced pressure to afford the crude product, which was further purified by column chromatography CH₂Cl₂:CH₃OH (300:1 to 100:3 (v/v)) to yield **5b'** in 73% yield (741.8 mg, 73%).¹H NMR (400 MHz, CDCl₃): δ 7.83 (d, *J* = 7.9 Hz, 1H), 7.74 (d, *J* = 15.4 Hz, 1H), 7.53–7.61 (m, 2H), 7.37–7.45 (m, 3H), 7.09–7.19 (m, 5H), 6.67 (d, *J* = 15.4 Hz, 1H), 4.80-4.88 (m, 1H), 4.74 (d, *J* = 7.0 Hz, 1H), 3.73 (s, 3H), 3.46–3.59 (m, 2H), 3.15-3.24 (m, 1H), 2.92-3.00 (m, 1H), 2.39-2.47 (m, 1H), 1.90–2.01 (m, 2H), 1.71-1.80 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 171.9, 170.7, 166.1, 143.3, 136.3, 135.0, 130.0, 129.3, 128.9 128.2, 127.9, 126.6, 117.8, 59.6, 53.3, 52.2, 47.2, 38.1, 26.5, 24.8; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₄H₂₇N₂O₄) requires m/z 407.1965, found m/z 407.1970.

3. General procedure for acylazidation of olefinic compounds



To a reaction mixture of catalyst **C1** (3.5 mg, 0.006 mmol, 2 mol%) and a fine powder PhIO (198.0 mg, 0.9 mmol, 3.0 equiv) in a 25 mL-Schlenk tube were added a aqueous solution of NaN₃ (4.0 mL, 0.3 M, 1.2 mmol, 4.0 equiv.), freshly distilled or purified aldehyde (1.5 mmol, 5.0 equiv.), and olefin **1** (0.3 mmol) under a nitrogen atmosphere. Then 2.4 mL EtOAc was added to the above reaction mixture and the reaction was stirred at room temperature. After the completion of the reaction as judged by TLC analysis (the reaction generally completed when the solid PhIO disappeared), the reaction mixture was extracted with EA (20.0 mL×1) and CH₂Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to give the desired products. (Note: Grinding the solid PhIO into very fine powder and removing oxygen are

necessary for an efficient reaction).

4. Analytical data

1-azido-1-phenylhexan-3-one (3a):

Compound 3a was synthesized according to the general procedure using 3.0 equiv PhIO (0.9 _{n-Pr} mmol, 198.1 mg) as a colorless oil in 75% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.31–7.40 (m, 5H), 5.05 (dd, *J* = 4.8, 9.0 Hz, 1H), 2.95 (dd, *J* = 9.0, 16.9 Hz, 1H), 2.70 (dd, *J* = 4.8, 16.9 Hz, 1H), 2.31–2.46 (m, 2H), 1.55–1.64 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.4, 139.0, 128.9, 128.4, 126.7, 61.2, 48.8, 45.5, 16.9, 13.6; HRMS (ESI+) exact mass calculated for $[M+Na]^+$ ($C_{12}H_{15}N_3NaO$) requires m/z 240.1113, found m/z 240.1118.

1-azido-4-ethyl-1-phenylhexan-3-one (3b):



Compound 3b was synthesized according to the general procedure using 3.0 equiv PhIO (0.9 , Et mmol, 198.3 mg) as a colorless oil in 55% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.30-7.39 (m, 5H), 5.09 (dd, *J* = 4.8, 8.7 Hz, 1H), 2.98 (dd, *J* = 8.8, 17.4 Hz, 1H), 2.71 (dd, *J* = 4.8, 17.4 Hz,

1H), 2.26-2.33 (m, 1H), 1.54–1.67 (m, 2H), 1.37–1.51 (m, 2H), 0.84 (t, J = 7.4 Hz, 3H), 0.77 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 210.8, 139.2, 128.8, 128.4, 126.8, 61.1, 55.9, 48.4, 23.8, 23.7, 11.6, 11.6; HRMS (ESI+) exact mass calculated for $[M+Na]^+$ ($C_{14}H_{19}N_3NaO$) requires m/z 268.1426, found m/z 268.1423.

3-azido-1-cyclopropyl-3-phenylpropan-1-one (3c):



Compound 3c was synthesized according to the general procedure using 3.0 equiv PhIO (0.9 mmol, 198.6 mg) as a colorless oil in 57% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.30-7.40 (m,

5H), 5.05 (dd, J = 4.7, 8.9 Hz, 1H), 3.11 (dd, J = 8.9, 17.0 Hz, 1H), 2.89 (dd, J = 4.7, 17.0 Hz, 1H), 1.87–1.93 (m, 1H), 1.01– 1.11 (m, 2H), 0.84–0.94 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 207.10, 139.0, 128.8, 128.3, 126.7, 61.2, 49.4, 21.1, 11.2, 11.1; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₂H₁₃N₃NaO) requires m/z 238.0956, found m/z 238.0961.

3-azido-1,3-diphenylpropan-1-one (3d):



Compound 3d was synthesized according to the general procedure using 3.0 equiv PhIO (0.9 Ph mmol, 198.2mg) as a colorless oil in 58% yield; However, if this compound was stored at -20 °C for 12 h, it became a white solid. ¹H NMR (400 MHz, CDCl₃): δ 7.92–7.95 (m, 2H), 7.55–7.58 (m, 1H), 7.42-7.49 (m 2H), 7.36-7.42 (m, 4H), 7.30–7.35 (m, 1H), 5.26 (dd, J = 4.6, 8.7 Hz, 1H), 3.55 (dd, J = 8.7, 17.3 Hz, 1H), 3.25 (dd, J = 4.7, 17.3 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 196.4, 139.2, 136.4, 133.5, 128.9, 128.7, 128.4, 128.1, 126.8, 61.5, 45.2; HRMS (ESI+) exact mass calculated for $[M+Na]^+$ (C₁₅H₁₃N₃NaO) requires

m/z 274.0956, found m/z 274.0959.

1-azido-1-(p-tolyl)hexan-3-one (3e):

Compound 3e was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.6 mg) as a colorless oil in 82% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.19 (q, J = 8.3 Hz, 4H), 5.01 (dd, J = 4.9, 8.9 Hz, 1H), 2.93 (dd, J = 8.9, 16.8 Hz, 1H), 2.68 (dd, J = 4.9, 16.8 Hz, 1H), 2.30–2.45 (m, 2H), 2.34 (s, 3H), 1.54–1.64 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.3, 138.2, 135.8, 129.5, 126.6, 61.0, 48.7, 45.4, 21.0, 16.9, 13.5; HRMS (ESI+) exact mass calculated for $[M+Na]^+$ (C₁₃H₁₇N₃NaO) requires m/z 254.1269, found m/z 254.1269.

1-azido-1-(o-tolyl)hexan-3-one (3f):

Compound **3f** was synthesized according to the general procedure using 3.0 equiv PhIO (0.9 mmol, 198.0 mg) as a colorless oil in 62% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.32–7.34 (m, 1H), 7.17–7.26 (m, 3H), 5.31 (dd, *J* = 4.2, 8.8 Hz, 1H), 2.95 (dd, *J* = 9.2, 17.1 Hz, 1H), 2.68 (dd, *J* = 4.3, 17.1 Hz, 1H), 2.34–2.48 (m, 2H), 2.40 (s, 3H), 1.57–1.66 (m, 2H), 0.91 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.5, 137.0, 135.3, 130.9, 128.1, 126.5, 126.1, 57.6, 47.9, 45.5, 19.2, 17.0, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₃H₁₇N₃NaO) requires m/z 254.1269, found m/z 254.1274.

1-azido-1-(4-methoxyphenyl)hexan-3-one (3g):



Compound **3g** was synthesized according to the general procedure using 3.0 equiv PhIO (0.9 mmol, 198.1 mg) as a colorless oil in 71% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.25 (d, *J* = 8.7 Hz, 2H), 6.90 (d, *J* = 8.7 Hz, 2H), 5.00 (dd, *J* = 5.1, 8.8 Hz, 1H), 3.80 (s, 3H),

2.94 (dd, J = 8.8, 16.8 Hz, 1H), 2.69 (dd, J = 5.1, 16.8 Hz, 1H), 2.30-2.45 (m, 2H), 1.54–1.64 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.4, 159.6, 130.9, 128.0, 114.2, 60.8, 55.2, 48.7, 45.5, 16.9, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₃H₁₇N₃NaO₂) requires m/z 270.1218, found m/z 270.1219.

1-([1,1'-biphenyl]-4-yl)-1-azidohexan-3-one (3h):



Compound **3h** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.0 mg) as a colorless oil in 60% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.54-7.63 (m, 4H), 7.33-7.45 (m, 5H), 5.10 (dd, J = 4.9, 8.9 Hz, 1H), 2.98 (dd, J = 8.9, 17.0 Hz, 1H), 2.74 (dd, J = 4.9, 17.0 Hz, 1H), 2.32-2.49 (m, 2H), 1.56–1.65 (m, 2H), 0.90

(t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.3, 141.3, 140.3, 137.9, 128.8, 127.6, 127.5, 127.2, 127.0, 61.0, 48.8, 45.4, 16.9, 13.6; HRMS (ESI+) exact mass calculated for $[M+Na]^+$ (C₁₈H₁₉N₃NaO) requires m/z 316.1426, found m/z 316.1431.

1-azido-1-(naphthalen-2-yl)hexan-3-one (3i):



Compound **3i** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.6 mg) as a colorless oil in 53% yield; ¹H NMR (400 MHz, CDCl₃): δ

3i 7.78–7.86 (m, 4H), 7.46-7.51 (m, 2H), 7.42 (dd, J = 1.5, 8.5 Hz, 1H), 5.22 (dd, J = 4.8, 8.8 Hz, 1H), 3.02 (dd, J = 8.9, 17.0 Hz, 1H), 2.77 (dd, J = 4.8, 17.0 Hz, 1H), 2.30–2.46 (m, 2H), 1.55–1.64 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.3, 136.3, 133.1, 128.9, 128.0, 127.7, 126.5, 126.4, 126.0, 124.1, 61.4, 48.8, 45.4, 16.9, 13.5; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₆H₁₇N₃NaO) requires m/z 290.1269, found m/z 290.1267.

1-azido-1-(2-chlorophenyl)hexan-3-one (3j):



Compound **3j** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 232.0 mg) as a colorless oil in 49% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.46 (dd, *J* = 1.7, 7.6 Hz, 1H), 7.39 (dd, *J* = 1.4, 7.8 Hz, 1H), 7.25–7.33 (m, 2H), 5.55 (dd, *J* = 3.8, 9.2 Hz,

1H), 2.74-2.87 (m, 2H), 2.43 (t, J = 7.3 Hz, 2H), 1.60–1.69 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 207.0, 137.0, 132.3, 130.0, 129.3, 127.7, 127.4, 57.9, 47.8, 45.1, 17.1, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₂H₁₄N₃ClNaO) requires m/z 274.0723, found m/z 274.0719.

1-azido-1-(4-fluorophenyl)hexan-3-one (3k):

Compound 3k was synthesized according to the general procedure using 3.0 equiv PhIO (0.9



mmol, 198.9 mg) as a colorless oil in 70% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.28–7.33 (m, 2H), 7.03–7.09 (m, 2H), 5.05 (dd, J = 5.1, 8.6 Hz, 1H), 2.93 (dd, J = 8.6, 17.0 Hz, 1H), 2.69 (dd, J = 5.2, 17.0 Hz, 1H), 2.30–2.46 (m, 2H), 1.55–1.64 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.1, 162.5 (d, J = 245.9 Hz), 134.8 (d, J = 3.3 Hz), 128.5 (d, J = 8.2 Hz), 115.8 (d, J = 21.5 Hz), 60.5, 48.9, 45.4, 16.9, 13.5; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₂H₁₄N₃FNaO) requires m/z 258.1019, found m/z 258.1017.

1-azido-1-(4-bromophenyl)hexan-3-one (3l):



Compound **31** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 232.0 mg) as a colorless oil in 59% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.55–7.47 (d, *J* = 8.4, 2H), 7.21 (d, *J* = 8.4 Hz, 2H), 5.03 (dd, *J* = 5.1, 8.6 Hz, 1H), 2.92 (dd,

J = 8.6, 17.1 Hz, 1H, 2.68 (dd, J = 5.1, 17.1 Hz, 1H), 2.30-2.46 (m, 2H), 1.55-1.64 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H);¹³C NMR (100 MHz, CDCl₃): δ 207.0, 138.1, 132.0, 128.4, 122.3, 60.6, 48.8, 45.4, 16.9, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₂H₁₄N₃BrNaO) requires m/z 318.0218, found m/z 318.0213.

1-azido-1-(2,5-dimethylphenyl)hexan-3-one (3m):



Compound **3m** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.8 mg) as a colorless oil in 70% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.13 (s, 1H), 7.02-7.11 (m, 2H), 5.28 (dd, *J* = 4.1, 9.3 Hz, 1H), 2.94 (dd, *J* = 9.3, 17.1 Hz, 1H), 2.65 (dd, *J* = 4.1, 17.1 Hz, 1H), 2.36–2.45 (m, 2H), 2.32 (s, 3H), 2.29 (s, 3H), 1.57–1.66 (m,

2H), 0.91 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.5, 136.8, 136.0, 132.0, 130.8, 128.8, 126.7, 57.6, 48.0, 45.4, 21.0, 18.7, 17.0, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₄H₁₉N₃NaO) requires m/z 268.1426, found m/z 268.1423.

1-azido-1-(2-bromo-4-methylphenyl)hexan-3-one (3n):



Compound **3n** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.7 mg) as a colorless oil in 55% yield; ¹H NMR: (400 MHz, CDCl₃) δ 7.40 (s, 1H), 7.31 (d, *J* = 7.9 Hz, 1H), 7.15 (d, *J* = 7.7 Hz, 1H), 5.48 (dd, *J* = 4.2, 8.9 Hz, 1H), 2.72–2.84 (m, 2H), 2.42 (t, *J* = 7.3 Hz, 2H), 2.32 (s, 3H), 1.59–1.69 (m, 2H), 0.93 (t, 1.59–1.59 (m, 2H), 0.93 (t, 1.59))

J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.0, 139.9, 135.4, 133.6, 128.8, 127.6, 122.3 59.9, 48.0, 45.1, 20.7, 17.0, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₃H₁₆N₃BrNaO) requires m/z 332.0374, found m/z 332.0373.

1-azido-1-mesitylhexan-3-one (3o):



Compound **30** was synthesized according to the general procedure using 6.0 equiv PhIO (1.8 mmol, 398.0 mg) as a colorless oil in 73% yield; ¹H NMR (400 MHz, CDCl₃): δ 6.85 (s, 2H), 5.67 (dd, *J* = 4.2, 9.0 Hz, 1H), 3.10 (dd, *J* = 9.1, 17.2 Hz, 1H), 2.60 (dd, *J* = 4.2, 17.2 Hz, 1H), 2.38–2.48 (m, 2H), 2.42 (s, 6H), 2.25 (s, 3H),

 $1.56-1.65 \text{ (m, 2H)} 0.90 \text{ (t, } J = 7.4 \text{ Hz, 3H)}; {}^{13}\text{C NMR} (100 \text{ MHz, CDCl}_3): \delta 207.6, 137.6, 136.4, 131.9, 130.2, 56.8, 46.4, 45.4, 20.7, 20.7, 17.00, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₅H₂₁N₃NaO) requires m/z 282.1582, found m/z 282.1578.$

1-azido-1,1-diphenylhexan-3-one (3p):

Ph Ph 3p

Compound **3p** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.9 mg) as a colorless oil in 77% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.27-7.35 (m,

10H), 3.43 (s, 2H), 2.10 (t, J = 7.2 Hz, 2H), 1.37–1.43 (m, 2H), 0.74 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 206.6, 142.1, 128.4 127.8, 126.8, 70.4, 51.2, 46.1, 16.7, 13.4; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₈H₁₉N₃NaO) requires m/z 316.1426, found m/z 316.1430.

1-azido-1-cyclohexyl-1-phenylhexan-3-one (3q):



. Compound **3q** was synthesized according to the general procedure using 6 equiv PhIO (1.8 mmol, 396.0 mg) as a colorless oil in 50% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.22–7.35 (m, 5H), 3.22(d, *J* = 15.8 Hz, 1H), 3.13 (d, *J* = 15.8 Hz, 1H), 2.13–2.28 (m, 2H), 1.62–1.91 (m, 5H),

 $1.40-1.56 \text{ (m, 3H)}, 0.93-1.25 \text{ (m, 5H)}, 0.75 \text{ (t, } J = 7.4 \text{ Hz, 3H)}; {}^{13}\text{C NMR} (100 \text{ MHz, CDCl}_3): \delta 207.2, 140.2, 128.1, 127.1, 126.4, 70.9, 48.5, 48.1, 46.0, 27.6, 26.4, 26.1, 16.7, 13.4; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₈H₂₅N₃NaO) requires m/z 322.1895, found m/z 322.1890.$

2-azido-2-phenylheptan-4-one (3r):



Compound **3r** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.2 mg) as a colorless oil in 76% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.34–7.42 (m, 4H), 7.25-7.30 (m, 1H), 2.87 (s, 2H), 2.24-2.33 (m, 1H), 2.13-2.22 (m, 1H), 1.83 (s, 3H), 1.42–1.51 (m, 2H), 0.80 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 207.3, 142.7,

128.6, 127.7, 125.4, 64.6, 53.5, 46.2, 24.5, 16.7, 13.4; HRMS (ESI+) exact mass calculated for $[M+Na]^+$ (C₁₃H₁₇N₃NaO) requires m/z 254.1269, found m/z 254.1264.

2-azido-2-(4-(trifluoromethyl)phenyl)heptan-4-one (3s):

Compound **3s** was synthesized according to the general procedure using 4.0 equiv PhIO M_{e} (1.2 mmol, 264.1 mg) as a colorless oil in 55% yield; ¹H NMR: (400 MHz, CDCl₃) δ 7.63 G_{3s} (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 2.92 (s, 2H), 2.19-2.35 (m, 2H), 1.86 (s, 3H), 1.45-1.54 (m, 2H), 0.82 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 206.7, 146.9, 130.0, 126.0, 125.6, 124.0 (q, J = 270 Hz), 64.2, 53.1, 46.2, 24.7, 16.8, 13.5; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₄H₁₆F₃N₃NaO) requires m/z 322.1143, found m/z 322.1149.

1-azido-1,2-diphenylhexan-3-one (3t):



Compound **3t** (from cis-Stilbene) was synthesized according to the general procedure using 6.0 equiv PhIO (1.8 mmol, 396.6 mg) and 1 mol% catalyst (0.003 mmol, 1.7mg) as a colorless oil in 54% yield; ¹H NMR (400 MHz, CDCl₃): δ 6.96-7.05 (m, 4H), 7.10-7.17 (m, 6H), 5.18 (d, J =10.8 Hz, 1H), 3.95 (d, J = 10.9 Hz, 1H), 2.38–2.54 (m, 2H), 1.50–1.69 (m, 2H), 0.84 (t, J = 7.5 Hz,

3H); ¹³C NMR (100 MHz, CDCl₃): δ 208.2, 137.0, 134.0, 128.9, 128.6, 128.3, 128.1, 127.7, 127.5, 67.7, 63.9, 45.1, 16.9, 13.4; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₈H₁₉N₃NaO) requires m/z 316.1426, found m/z 316.1422.

2-azido-2-(benzo[b]thiophen-2-yl)heptan-4-one (3u) :



Compound **3u** was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 231.6 mg) and 2 mol% catalyst (0.006 mmol, 1.7 mg) as a colorless oil in 72% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.70–7.81 (m, 2H), 7.28–7.37 (m, 2H), 7.21 (d, *J* =

0.4 Hz, 1H), 2.98 (s, 2H), 2.24–2.43 (m, 2H), 1.95 (s, 3H), 1.47–1.58 (m, 2H), 0.83 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 206.6, 147.9, 139.2, 124.7, 124.5, 123.8, 122.2, 120.9, 63.1, 53.4, 46.2, 24.8, 16.8, 13.5; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₅H₁₇N₃NaOS) requires m/z 310.0990, found m/z 310.0986.

2-(azido(phenyl)methyl)-N,N-dibenzyl-3-oxohexanamide (3aa):



Compound **3aa** was synthesized according to the general procedure using 3.5 equiv PhIO (1.05 mmol, 231.0 mg) as a white solid in 55% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.24-7.49 (m, 15H), 5.50 (d, J = 10.6 Hz, 1H), 4.93 (d, J = 14.7 Hz, 1H), 4.53–4.78 (m, 2H),

3aa 4.50 (d, J = 15.2 Hz, 1H), 4.20 (d, J = 10.6 Hz, 1H), 2.00–2.19 (m, 2H), 1.18–1.27 (m, 2H), 0.59 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.5, 166.9, 136.7, 136.2, 136.0, 129.1, 129.0, 128.7, 128.3, 127.9, 127.9, 127.6, 126.7, 65.5, 62.6, 50.2, 49.3, 42.8, 16.3, 13.1; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₇H₂₉N₄O₂) requires m/z 441.2291, found m/z 441.2295.

2-(azido(phenyl)methyl)-N,N-diethyl-3-oxohexanamide (3ab):



2.35-2.43 (m, 1H), 2.12–2.20 (m, 1H), 1.26–1.37 (m, 2H), 1.30 (t, J = 7.2 Hz, 3H), 1.16 (t, J = 7.2 Hz, 3H), 0.66 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.9, 165.3, 136.4, 129.0, 128.9, 127.9, 65.3, 62.8, 42.4, 42.2, 41.2, 16.4, 14.5, 13.1, 12.8; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₁₇H₂₅N₄O₂) requires m/z 317.1972, found m/z 317.1969.

2-(azido(4-(trifluoromethyl)phenyl)methyl)-*N*,*N*-diethyl-3-oxohexanamide (3ab):



Compound **3ac** was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.2 mg) as a light yellow solid in 50% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, *J* = 8.2 Hz, 2H), 7.49 (d, *J* = 8.2 Hz, 2H), 5.47 (d, *J* = 10.5 Hz, 1H), 4.5 (d, *J* = 10.5 Hz, 1H), 3.52–3.61 (m, 2H), 3.35–3.47 (m, 2H), 2.31–2.39 (m, 1H), 2.16-2.24(m, 1H),

1.30-1.41 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H), 1.18 (t, J = 7.2 Hz, 3H), 0.69 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.3, 165.0, 140.9, 131.1, 128.4, 126.0 (q, J = 4.0 Hz), 123.8 (q, J = 270.0 Hz), 64.7, 62.6 , 42.6, 41.4, 16.5, 14.6, 13.2, 12.8; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₁₈H₂₄F₃N₄O₂) requires m/z 385.1846, found m/z 385.1843.

2-(azido(2-bromophenyl)methyl)-N,N-diethyl-3-oxohexanamide (3ad):



Compound **3ad** was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 265.0 mg) as a white solid in 62% yield; ¹H NMR (400 MHz, $CDCl_3$): δ 7.61 (d, *J* = 7.9 Hz, 1H), 7.32–7.36 (m, 2H), 7.18–7.22 (m, 1H), 6.01 (d, *J* = 10.1 Hz, 1H), 4.22 (d, *J* = 10.1 Hz, 1H), 3.46–3.58 (m, 2H), 3.26–3.41 (m, 2H), 2.44–2.52 (m, 1H), 2.21–2.29 (m, 1H), 1.29–1.44

(m, 2H), 1.25 (t, J = 7.2 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H), 0.67 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 203.4, 165.1, 135.6, 133.6, 130.4, 129.7, 128.1, 124.2, 63.3, 61.6, 42.3, 41.7 41.3, 16.4, 14.5, 13.1, 12.8; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₁₇H₂₄BrN₄O₂) requires m/z 395.1077, found m/z 395.1074.

2-(azido(3-fluorophenyl)methyl)-N,N-diethyl-3-oxohexanamide (3ae):



Compound **3ae** was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.0 mg) as a white solid in 50% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.33-7.38 (m, 1H), 7.15 (d, *J* = 7.7 Hz, 1H), 7.02–7.08 (m, 2H), 5.41 (d, *J* = 10.6 Hz, 1H), 4.03 (d, *J* = 10.6 Hz, 1H), 3.52-3.61 (m, 2H), 3.33–3.44 (m, 2H), 2.33–2.41 (m, 1H), 2.16-2.24 (m, 1H),

1.26-1.42 (m, 2H), 1.30 (t, *J* = 7.2 Hz, 3H), 1.17 (t, *J* = 7.1 Hz, 3H), 0.69 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz,

 $CDCl_3$): δ 202.5, 165.0, 162.9 (d, J = 246.0 Hz), 139.1 (d, J = 6.0 Hz), 130.5 (d, J = 9.0 Hz), 123.7 (d, J = 3.0 Hz), 116.1 (d, J = 20.0 Hz),114.8 (d, J = 22 Hz), 64.7, 62.6, 42.5, 41.2, 16.4, 14.5, 13.2, 12.8; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₁₇H₂₄FN₄O₂) requires m/z 335.1878, found m/z 335.1882.

2-(azido(4-fluorophenyl)methyl)-N,N-diethyl-3-oxohexanamide (3af):

Compound **3af** was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.0 mg) as a white solid in 59% yield; ¹H NMR (400 MHz, $CDCl_3$): δ 7.34-7.37 (m, 2H), 7.05-7.09 (t, J = 8.3 Hz, 2H), 5.42 (d, J = 10.6 Hz, 1H), 4.04 (d, J = 10.6 Hz, 1H), 3.53-3.62 (m, 2H), 3.32–3.44 (m, 2H), 2.34–2.42 (m, 1H), 2.13–2.21 (m, 1H), 1.28–1.40 (m, 2H), 1.30 (t, J = 7.0 Hz, 3H), 1.17 (t, J = 6.9 Hz, 3H), 0.68 (t, J = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.7, 165.2, 162.8 (d, J = 247.0 Hz, 132.4 (d, J = 3.0 Hz), 129.7 (d, J = 9.0 Hz), 116.0 (d, J = 22.0 Hz), 64.5, 62.9, 42.4, 42.3, 41.2, 16.4, 14.5, 13.1, 12.7; HRMS (ESI+) exact mass calculated for $[M+H]^+$ (C₁₇H₂₄FN₄O₂) requires m/z 335.1878, found m/z 335.1883.

2-(azido(4-chlorophenyl)methyl)-*N*,*N*-diethyl-3-oxohexanamide (3ag):



Compound 3ag was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.2 mg) as a white solid in 53% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.36 (d, *J* = 8.5 Hz, 2H), 7.30 (d, *J* = 8.5 Hz, 2H), 5.40 (d, *J* = 10.6 Hz, 1H), 4.02 (d, *J* = 10.6 Hz,

1H), 3.52-3.58 (m, 2H), 3.32-3.44 (m, 2H), 2.34-2.41 (m, 1H), 2.13-2.21 (m, 1H), 1.26-1.41 (m, 2H), 1.30 (t, *J* = 7.2 Hz, 3H), 1.17 (t, *J* = 7.1 Hz, 3H), 0.69 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.6, 165.1, 135.1, 134.8, 129.2, 129.1, 64.5, 62.7, 42.4, 42.3, 41.2, 16.4, 14.5, 13.2, 12.8; HRMS (ESI+) exact mass calculated for $[M+H]^+$ ($C_{17}H_{24}ClN_4O_2$) requires m/z 351.1582, found m/z 351.1577.

2-(azido(3,4-difluorophenyl)methyl)-*N*,*N*-diethyl-3-oxohexanamide (3ah):



Compound **3ah** was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.9 mg) as a white solid in 67% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.10-7.22 (m, 3H), 5.39 (d, J = 10.5 Hz, 1H), 3.97 (d, J = 10.5 Hz, 1H), 3.51–3.61 (m, 2H), 3.34–3.45 (m, 2H), 2.32-2.40 (m,1H), 2.17-2.25 (m, 1H), 1.35–1.43 (m, 2H), 1.31 (t, J = 7.2 Hz, 3H, 1.17 (t, J = 7.1 Hz, 3H), 0.71 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.3, 164.9, 150.5 (dd, J = 5.0, 254.0 Hz), 150.4 (dd, J = 5.0, 240.0 Hz), 134.0 (t, J = 5.0 Hz), 124.2 (dd, J = 3.0, 6.0 Hz), 117.8 (d, J = 5.0, 254.0 Hz), 117.8 (d, J = 5.

= 17.0 Hz), 116.9 (d, J = 17.0 Hz), 64.3, 62.7, 42.5, 41.3, 16.5, 14.5, 13.2, 12.8; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₁₇H₂₃FN₄O₂) requires m/z 353.1784, found m/z 353.1782.

2-(azido(2-methoxyphenyl)methyl)-N,N-diethyl-3-oxohexanamide (3ai):



Compound **3ai** was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.2 mg) as a white solid in 54% yield; ¹H NMR (400 MHz, $CDCl_3$): δ 7.22-7.37 (m, 2H), 6.86-7.01 (m, 2H), 5.82 (d, J = 10.7 Hz, 1H), 4.33 (d, J = 10.7 Hz, 1H), 3.88 (s, 3H),

3.49–3.62 (m, 2H), 3.29–3.46 (m, 2H), 2.41-2.52 (m, 1H), 2.17-2.27 (m, 1H), 1.22–1.42 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H), 0.66 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 203.7, 165.8, 157.0, 130.2, 129.3, 124.0, 120.9, 111.1, 61.1, 60.0, 55.4, 42.6, 41.5, 41.1, 16.3, 14.4, 13.1, 12.8; HRMS (ESI+) exact mass calculated for $[M+H]^+$ (C₁₈H₂₇N₄O₃) requires m/z 347.2078, found m/z 347.2081.

2-(azido(o-tolyl)methyl)-*N*,*N*-diethyl-3-oxohexanamide (3aj):

Compound 3aj was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.4 mg) as

a colorless oil in 57% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.21-7.26 (m, 4H), 5.70 (d, J = 10.6 Hz, 1H), 4.27 (d, J = 10.6 Hz, 1H), 3.52-3.67 (m, 2H), 3.33–3.46 (m, 2H), 2.53 (s, 3H), 2.33-2.41 (m, 1H), 2.03-2.11 (m, 1H), 1.25–1.37 (m, 2H), 1.32 (t, *J* = 7.2 Hz, 3H), 1.17 (t, *J* = 7.1 Hz_a; β H), 0.63 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.9, 165.4, 136.9, 134.3, 131.3, 128.8, 127.3, 126.5, 61.6, 61.1, 42.4, 42.1, 41.3, 19.7, 16.4, 14.5, 13.1, 12.8; HRMS (ESI+) exact mass calculated for $[M+H]^+$ (C₁₈H₂₇N₄O₂) requires m/z 331.2129, found m/z 331.2124.

2-(azido(m-tolyl)methyl)-N,N-diethyl-3-oxohexanamide (3ak):



Compound 3ak was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.9 mg) as a colorless oil in 67% yield; ¹H NMR (400 MHz, CDCl₃): § 7.20-7.29 (m, 1H), 7.10-7.17 (m, 3H), 5.37 (d, *J* = 10.6 Hz, 1H), 4.07 (d, *J* = 10.6 Hz, 1H), 3.5–3.64 (m, 2H), 3.29-3.43 (m, 2H), 2.33–2.45 (m, 1H), 2.36 (s, 3H), 2.12–2.22 (m, 1H), 1.26–1.40 (m, 2H),

1.29 (t, J = 7.2 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H), 0.66 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 203.0, 165.3, 138.7, 136.12, 129.8, 128.8, 128.5, 124.9, 65.3, 62.8, 42.3, 42.1, 41.2, 21.3, 16.4, 14.5, 13.1, 12.8; HRMS (ESI+) exact mass calculated for $[M+H]^+$ ($C_{18}H_{27}N_4O_2$) requires m/z 331.2129, found m/z 331.2134.

2-(azido(naphthalen-2-yl)methyl)-N.N-diethyl-3-oxohexanamide (3al):



367.2128.

Compound 3al was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.1 mg) as a white solid in 70% yield; ¹H NMR (400 MHz, CDCl₃): δ 8.33 (d, J = 8.5 Hz, 1H), 7.81-7.93 (m, 2H), 7.60–7.66 (m, 1H), 7.42–7.58 (m, 3H), 6.24 (d, J = 10.3 Hz, 1H), 4.47 (d, J = 10.4 Hz, 1H), 3.55–3.72 (m, 2H), 3.30–3.46 (m, 2H), 2.29-2.44 (m, 1H), 1.94-2.10 (m, 1H), 1.31 (t, J = 7.2 Hz, 3H), 1.09–1.24 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H), 0.48 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 203.3, 165.4, 134.1, 131.7, 131.2, 129.8, 129.1, 127.0, 126.2, 125.1, 122.9, 62.0, 42.4, 41.8, 41.3, 16.3, 14.5, 13.0, 12.9; HRMS (ESI+) exact mass calculated for $[M+H]^+$ (C₂₁H₂₇N₄O₂) requires m/z 367.2129, found m/z

2-(azido(2,3-dimethoxyphenyl)methyl)-N,N-diethyl-3-oxohexanamide (3am):



as a white solid in 74% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.05 (t, J = 8.0 Hz, 1H), 6.86–6.94 (m, 2H), 5.71 (d, *J* = 10.8 Hz, 1H), 4.37 (d, *J* = 10.8 Hz, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 3.50-3.64 (m, 2H), 3.32-3.49 (m, 2H), 2.39-2.51 (m, 1H), 2.17-2.28 (m, 1H), 1.26-1.41 (m, 2H), 1.29 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H), 0.67 (t, J = 7.4 Hz,

3H; ¹³C NMR (100 MHz, CDCl₃): δ 203.4, 165.8, 152.9, 147.3, 129.7, 124.3, 121.0, 113.0, 61.3, 61.2, 60.8, 55.7, 42.4, 41.8, 41.2, 16.5, 14.5, 13.2, 12.9; HRMS (ESI+) exact mass calculated for $[M+H]^+(C_{19}H_{29}N_4O_4)$ requires m/z 377.2183, found m/z 377.2184.

Compound **3am** was synthesized according to the general procedure using 5.0 equiv PhIO (1.5 mmol, 330.9 mg)

2-(azido(3,4,5-trimethoxyphenyl)methyl)-N,N-diethyl-3-oxohexanamide (3an):



Compound **3an** was synthesized according to the general procedure using 5.0 equiv PhIO (1.5 mmol, 330.2 mg) as a white solid in 78% yield; ¹H NMR (400 MHz, CDCl₃): δ 6.54 (s, 2H), 5.37 (d, J = 10.4 Hz, 1H), 4.02 (d, J = 10.4 Hz, 1H), 3.88 (s, 6H), 3.86 (s,

3H), 3.48-3.65 (m, 2H), 3.31-3.46 (m, 2H), 2.31-2.43 (m, 1H), 2.14-2.24 (m, 1H), 1.32–1.43 (m, 2H), 1.29 (t, *J* = 7.2 Hz, 3H), 1.16 (t, *J* = 7.1 Hz, 3H), 0.69 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 202.9, 165.1, 153.4, 138.3, 131.9, 105.0, 65.4, 62.9, 60.7, 56.2, 42.3, 41.1, 16.4, 14.4, 13.1, 12.7; HRMS (ESI+) exact mass calculated for $[M+H]^+$ ($C_{20}H_{30}N_4NaO_5$) requires m/z 429.2108, found m/z 429.2105.

(8R,9S,13S,14S)-3-(1-azido-3-oxo-3-phenylpropyl)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclo penta[a]phenanthren-17-one (4a):



Compound 4a was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.4 mg) as a colorless oil in 45% yield; This compound is nearly a 1:1 mixture of diastereomers, which can be separated by HPLC on a chiral stationary phase ((IA column, hexane: *i*-PrOH = 95:5, 0.5 mL/min, peak 1: 57.5 min (47%); Peak 2: 67.5 min (53%)). ¹H NMR (400 MHz, CDCl₃): δ 7.95 (d, J = 7.7 Hz, 2H), 7.58 (t, J = 7.3 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.32 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 7.13 (s, 1H), 5.20 (dd, J = 4.5, 8.7) Hz, 1H), 3.55 (dd, J = 8.8, 17.3 Hz, 1H), 3.25 (dd, J = 4.5, 17.3 Hz, 1H), 2.90–3.00 (m, 2H), 2.51 (dd, J = 8.9, 19.0

Hz, 1H), 2.38–2.46 (m, 1H), 2.26-2.36 (m, 1H), 2.01–2.21 (m, 3H), 1.97 (d, J = 11.5 Hz, 1H), 1.42–1.68 (m, 6H), 0.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 220.8, 196.5, 140.0, 137.1, 136.7, 136.5, 133.4, 128.7, 128.1, 127.4, 125.9, 124.1, 61.3, 50.5, 47.9, 45.1, 44.3, 37.9, 35.8, 31.5, 29.4, 26.3, 25.6, 21.5, 13.8; HRMS (ESI+) exact mass calculated for [M+H]+ (C₂₇H₂₉NaN₃O₂) requires m/z 450.2157, found m/z 450.2156.

(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl (2-(azido(phenyl)methyl)-3-oxohexanoyl)-L-prolinate (4b):



Compound 4b was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 265.7 mg) as a colorless oil in 47% yield; ¹H NMR (400 MHz, CDCl₃) : δ 7.34-7.41 (m, 5H), 7.25-7.29 (m, 1H), 6.81-6.89 (m,

2H), 5.40 (d, J = 10.6 Hz, 1H), 4.82 (dd, J = 4.5, 8.5 Hz, 1H), 4.04 (d, J = 10.6 Hz, 1H), 3.81 (t, J = 6.3 Hz, 2H), 2.84-2.95 (m, 2H), 2.50 (dd, J = 8.9, 19.0 Hz), 2.36–2.43 (m, 2H), 2.35–2.26 (m, 2H), 2.35–2 3H), 2.20–2.11 (m, 3H), 2.07–1.93 (m, 4H), 1.60 (dd, J = 7.7, 10.7 Hz, 2H), 1.56–1.45 (m, 4H), 1.30–1.25 (m, 2H), 0.90 (s, 3H), 0.56 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) : δ 220.6, 201.5, 170.5, 165.1, 148.4, 138.0, 137.5, 136.4, 129.0, 128.9, 127.9, 126.3, 121.3, 118.4, 64.7, 64.2, 59.4, 50.4, 47.9, 47.7, 44.1, 42.8, 37.9, 35.8, 31.5, 29.3, 29.2, 26.3, 25.7, 24.9, 21.5, 16.2, 13.8, 13.0; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₃₆H₄₃N₄O₅) requires m/z 611.3233, found m/z 611.3229.

methyl (2-(azido(phenyl)methyl)-3-oxohexanoyl)-D-prolyl-D-valinate (5a)



Compound 5a was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.5 mg) as a colorless oil in 64% yield; ¹H NMR

(400 MHz, CDCl₃): δ 7.35–7.39 (m, 5H), 7.06 (d, J = 8.5 Hz, 1H), 5.40 (d, J = 10.6 Hz, 1H), 4.66–4.73 (m, 1H), 4.46 (dd, J = 5.0, 8.5 Hz, 1H), 4.07 (d, J =

10.6 Hz, 1H), 3.72–3.77 (m, 5H), 2.22-2.29 (m, 2H), 2.10-2.21 (m, 2H), 2.00-2.09 (m, 2H), 1.24–1.37 (m, 2H), 0.91 (d, J = 3.3 Hz, 3H), 0.89 (d, J = 3.3 Hz, 3H), 0.65 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 201.4, 172.1, 170.7, 166.1, 136.3, 129.0, 128.9, 127.8, 64.7, 63.7, 60.3, 57.4, 52.0, 48.3, 43.6, 31.0, 27.8, 25.0, 18.9, 17.6, 16.2, 13.1; HRMS (ESI+) exact mass calculated for $[M+H]^+$ ($C_{24}H_{34}N_5O_5$) requires m/z 472.2560, found m/z 472.2565.

methyl (2-(azido(phenyl)methyl)-3-oxohexanoyl)-L-prolyl-D-phenylalaninate (5b):



Compound 5b was synthesized according to the general procedure using 4.0 equiv PhIO (1.2 mmol, 264.0 mg) as a colorless oil in 44% yield; ¹H NMR (400 MHz, CDCl₃): δ 7.34-7.40 (m, 5H), 7.22-7.29 (m, 3H), 7.12-7.17 (m, 2H), 6.84 (d, J = 7.6 Hz, 1H), 5.38 (d, J = 10.5 Hz, 1H), 4.74-4.81 (m, 1H),

4.60-4.65 (m, 1H), 4.03 (d, J = 10.5 Hz, 1H), 3.64-3.73 (m, 5H), 3.03-3.15 (m, 2H), 2.18-2.28 (m, 3H),

1.96-2.06 (m, 3H), 1.25–1.35 (m, 2H), 0.63 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 201.8, 171.6, 170.5, 166.0, 136.3, 135.8, 129.2, 129.0, 128.9, 128.4, 127.8, 126.7, 64.7, 63.9, 60.4, 53.5, 52.2, 48.1, 43.3, 37.9, 28.2, 24.7, 16.3, 13.1; HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₈H₃₄N₅O₅) requires m/z 520.2560, found m/z 520.2557.

5. Mechanistic Study

(1) the generation of acyl radical :

$$EtO_{2}C$$

$$N=N$$

$$CO_{2}Et$$

$$N=N$$

$$CO_{2}Et$$

$$N=NCHO$$

$$(C1 (2 mol\%))$$

$$PhIO (3.0 equiv.)$$

$$EtO_{2}C$$

$$N=NH$$

$$O= (CO_{2}Et)$$

$$O= (CO_{2}Et)$$

$$n-Pr$$

To a reaction mixture of catalyst **C1** (1.2 mg, 0.002 mmol, 2 mol%) and PhIO (66.8mg, 0.3 mmol, 3.0 equiv.) in a 10 mL-Schlenk tube were added 1.0 mL H₂O, *n*-butylaldehyde (44.0 uL, 0.5 mmol, 5.0 equiv.), and diethyl (E)-diazene-1,2-dicarboxylate (16.0 uL, 0.1 mmol, 1.0 equiv.) under a nitrogen atmosphere. Then 1.0 mL EtOAc was added to the above reaction mixture and the reaction was stirred at room temperature. After the completion of the reaction as judged by TLC analysis, the reaction mixture was extracted with EA (10.0 mL×1) and CH $_2$ Cl₂ (8.0 mL×2). The combined organic la yer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to give the desired products **6** (23.5 mg, 0.095mmol, 95%). Its spectral data obtained were identical with those reported in literature.¹¹

(2) Radical clock experiment :



To a reaction mixture of catalyst **C1** (1.7 mg, 0.003 mmol, 1 mol%) and PhIO (339.9 mg, 1.5 mmol, 5.0 equiv.) were added a aqueous solution of NaN₃ (4.0 mL, 0.3 M, 1.2 mmol, 4.0 equiv.), *n*-butylaldehyde (132.0 uL, 1.5 mmol, 5.0 equiv.), and olefin **1u** (47.5mg, 0.3 mmol, 1.0 equiv.) under a nitrogen atmosphere. Then 2.4 mL EtOAc was added to the above reaction mixture and the reaction was stirred at room temperature. After the completion of the reaction as judged by TLC analysis, the reaction mixture was extracted with EA (20.0 mL×1) and CH₂Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to obtain a colourless oil **3v** (8.8 mg, 0.03 mmol, 11%). ¹H NMR (400 MHz, CDCl₃): δ 7.28-7.40 (m, 5H), 5.23 (t, *J* = 6.3 Hz, 1H), 4.48 (t, *J* = 7.2 Hz, 1H), 3.03 (s, 2H), 2.45–2.63 (m, 2H), 2.32 (t, *J* = 7.4 Hz, 2H), 1.50-1.63 (m, 2H), 1.58 (s, 3H), 0.88 (t, *J* = 7.4 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 209.2, 139.3, 132.6, 128.7, 128.2, 126.8, 124.2, 66.0, 53.8, 43.6, 35.0, 17.1, 16.6, 13.6; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₆H₂₁N₃NaO) requires m/z 294.1582, found m/z 294.1581.



To a reaction mixture of catalyst **C1** (3.4 mg, 0.006 mmol, 2 mol%) and PhIO (399.7 mg, 1.8 mmol, 6.0 equiv.) were added a aqueous solution of NaN₃ (4.0 mL, 0.3 M, 1.2 mmol, 4.0 equiv.), benzaldehyde (150.0 uL, 1.5 mmol, 5.0 equiv.), and olefin **1w** (56.4 mg, 0.3 mmol, 1.0 equiv.) under a nitrogen atmosphere. Then 2.4 mL EtOAc was added to the above reaction mixture and the reaction was stirred at room temperature. After the completion of the reaction as judged by TLC analysis, the reaction mixture was extracted with EA (20.0 mL×1) and CH₂Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to obtain a light yellow oil **3w** (12.2 mg, 0.03 mmol, 12%). Major isomer: ¹H NMR (400 MHz, CDCl₃): δ 7.83-7.90 (m, 2H), 7.53-7.59 (m, 1H), 7.40-7.50 (m, 2H), 7.21-7.29 (m, 3H), 7.15-7.20 (m, 2H), 5.11 (dq, *J* = 1.2, 9.3 Hz, 1H), 4.40 (d, *J* = 7.9 Hz, 1H), 4.12 (dd, 1H, *J* = 8.1, 9.3 Hz), 3.57 (d, *J* = 15.2 Hz, 1H), 3.51 (d, *J* = 15.2 Hz, 1H), 3.32 (s, 3H), 1.41 (d, *J* = 1.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 197.3, 136.7, 136.4, 136.3, 133.1, 128.5, 128.4, 128.3, 128.2, 127.8, 126.1, 80.2, 69.1 56.3, 49.1, 17.1; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₂₀H₂₁N₃NaO₂) requires m/z 358.1531, found m/z 358.1528.

Minor: ¹H NMR (400 MHz, CDCl₃): δ 7.94-7.99 (m, 2H), 7.53-7.59 (m, 1H), 7.41-7.49 (m, 2H), 7.21-7.29 (m, 5H,), 5.29 (dq, J = 1.2, 9.1 Hz, 1H), 4.67 (d, J = 4.4 Hz, 1H), 4.13 (dd, 1H, 1H, J = 4.3, 9.2 Hz,), 3.73 (d, J = 15.2 Hz, 1H), 3.65 (d, J = 15.2 Hz, 1H), 3.26 (s, 3H), 1.42 (d, 3H, J = 1.3 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 197.5, 137.0, 136.5, 136.2, 133.2, 128.6, 128.4, 128.3, 128.1, 127.7, 125.5, 80.2, 68.8, 56.3, 49.5, 17.0. HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₂₀H₂₁N₃NaO₂) requires m/z 358.1531, found m/z 358.1528.

(3) competitive experiment:

To a reaction mixture of catalyst **C1** (3.5 mg, 0.006 mmol, 2 mol%) and PhIO (137.2 mg, 0.6 mmol, 2.0 equiv.) were added a aqueous solution of NaN₃ (2.0 mL, 0.3 M, 0.6 mmol, 2.0 equiv.), *n*-butylaldehyde (53.0 uL, 0.6 mmol, 2.0 equiv.), olefin **1a** (35.0 uL, 0.3 mmol) and **1p** (53.0 uL, 0.3 mmol) under a nitrogen atmosphere. Then 2.4 mL EtOAc was added to the above reaction mixture and the reaction was stirred at room temperature. When the solid PhIO disappeared, the reaction mixture was extracted with EA (20.0 mL×1) and CH₂Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to obtain **3a** (5.5 mg, 8%), **3p** (38.5 mg, 46%). ¹H NMR ratio of crude mixture for **3p**:**3a** is 10.0:1 (20 min); 4.3:1 (1 h); 3.7:1 (2 h, full cosumption of PhIO).

(4) in absence of NaN₃:

Ph + n-PrCHO
$$\xrightarrow{\text{C1} (2 \text{ mol}\%)}{\text{PhIO} (3.0 \text{ equiv.})}$$
 Ph $\xrightarrow{\text{OH}}{\text{Ph}}$ OH O
H₂O/EtOAc, rt Ph $\xrightarrow{\text{Ph}}$ n-Pr

To a reaction mixture of catalyst C1 (2.6 mg, 0.004 mmol, 2 mol%) and PhIO (136.0 mg, 0.6 mmol, 3.0 equiv.) in a 10 mL-Schlenk tube were added H_2O (2.6 mL), n-butylaldehyde (88 uL, 1.0 mmol, 5.0 equiv.), and olefin 1p (35 uL, 0.2 mmol, 1.0 equiv) under a nitrogen atmosphere. Then 1.6 mL EtOAc was added to the above reaction mixture and the reaction was stirred for about 48 h at room temperature. After the completion of the reaction as judged by TLC analysis (the reaction generally completed when the solid PhIO disappeared), the reaction mixture was extracted with EA (20.0 mL×1) and CH $_2$ Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to give the desired product **9** (22.8 mg, 41%). ¹H NMR (400 MHz, CDCl₃): δ 7.35-7.40 (m, 4H), 7.26-7.32 (m, 4H), 7.17-7.23 (m, 2H), 3.38 (s, 2H), 2.39 (t, *J* = 7.2 Hz, 2H), 1.47–1.58 (m, 2H), 0.83 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 212.7, 146.2, 128.2, 126.9, 125.6, 77.04, 52.1, 46.5, 16.7, 13.5; HRMS (ESI+) exact mass calculated for [M+Na]⁺ (C₁₈H₂₀NaO₂) requires m/z 291.1361, found m/z 291.1357.

(5) in the presence of a large excess of competitive nucleophiles:



To a reaction mixture of catalyst **C1** (3.5 mg, 0.006 mmol, 2 mol%) and PhIO (198.0 mg, 0.9 mmol, 3.0 equiv.) in a 25 mL-Schlenk tube were added a aqueous solution of NaN₃ (4.0 mL, 0.3 M, 1.2 mmol, 4.0 equiv.), *n*butylaldehyde (132 uL, 1.5 mmol, 5.0 equiv.), methanol (240.0 uL, 6.0 mmol, 20.0 equiv.) and olefin **1a** (35.0 uL, 0.3 mmol, 1.0 equiv.) under a nitrogen atmosphere. Then 2.4 mL EtOAc was added to the above reaction mixture and the reaction was stirred at room temperature. After the completion of the reaction as judged by TLC analysis, the reaction mixture was extracted with EA (20.0 mL×1) and CH $_2$ Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to give the desired products **3a** (39.1 mg, 0.18 mmol, 60%).

(6) the observation of the competition between two radical rebound approaches:



To a reaction mixture of catalyst **C1** (3.5 mg, 0.006 mmol, 2 mol%), NaN₃ (78.1mg, 1.2 mmol, 4.0 equiv.), 4Å MS (61.1 mg) and PhIO (198.0 mg, 0.9 mmol, 3.0 equiv.) in a 25 mL-Schlenk tube were added 4.0 mL CH₃CN under a nitrogen atmosphere. Then *n*-butylaldehyde (132.0 uL, 1.5 mmol, 5.0 equiv.) and olefin **1p** (53.0 uL, 0.3mmol, 1.0 equiv.) was added to the above reaction mixture and the reaction was stirred at room temperature. After the completion of the reaction as judged by TLC analysis, the reaction mixture was evaporated under reduced pressure to afford the crude product, which was purified by flash chromatography on silica gel to give the desired products **3p** (39.5 mg, 0.13 mmol, 44%) and **9** (24.2 mg, 0.09 mmol, 30%).

(7) Evaluation of factors affecting diastereoselectivity:





General experimental procedure:

To a reaction mixture of catalyst C (2 mol%) and a fine powder PhIO in a 25 mL-Schlenk tube were added a aqueous solution of NaN₃ (4.0 mL, 0.3 M, 1.2 mmol, 4.0 equiv.), freshly distilled aldehyde (1.5 mmol, 5.0 equiv.), and olefin (0.3 mmol) under a nitrogen atmosphere. Then 2.4 mL EtOAc was added to the above reaction mixture and the reaction was stirred at room temperature. After the completion of the reaction as judged by TLC analysis (the reaction generally completed when the solid PhIO disappeared), the reaction mixture was extracted with EA (20.0 mL×1) and CH₂Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the mixture for ¹HNMR analysis to determine diastereoselectivity.

Standard reaction condition: catalyst C1, room temperature, product 3ai, dr 5:1.

Experiment 1: catalyst C1, heating at 60 °C: product 3ai, dr 3:1.

Experiment 2: After standard reaction was complete, the reaction mixture was extracted with EA (20.0 mL×1) and CH₂Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the mixture, which was filtrated through a short silica gel column to give the crude products. Then the crude products were dissolved in EA/H₂O (0.6/1, 6.4 mL) and 20 mol% DIPEA (diisopropyl ethyl amine) was added to this mixture. The reaction was stirred at room temperature for 12 h, product **3ai**, dr 4:1. *Experiment 3:* After standard reaction was complete, the reaction mixture was extracted with EA (20.0 mL×1) and CH₂Cl₂ (15.0 mL×2). The combined organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude products. The crude products were dissolved in EA/H₂O (0.6/1, 6.4 mL) and 20 mol% A_2CO_3 was added to this mixture. The reaction was stirred at room temperature for 12 h, product **3ai**, dr 3:1.

Experiment 4: using 2 mol% C4 instead of C1: product 3ai, dr 2.5:1.

Experiment 5: using 2 mol% C5 instead of C1: product 3ai, dr 4:1.

Experiment 6: using 2 mol% C7 (epimer of C5, chiral) instead of C1: product 3ai, dr 3:1.

Experiment 7: using 2 mol% C1, room temperature, product 3t, dr 5:1

Experiment 8: using 2 mol% C4 instead of C1, room temperature, product 3t, dr 3:1

X-ray crystallographic data



Table 1: Crystal data and structure refinement for 3aa

Empirical formula	$C_{27}H_{28}N_4O_2$
Formula weight	440.53
Temperature/K	298 (2)
Crystal system	monoclinic
Space group	C2/c
a/Å	22.679 (7)
b/Å	10.176 (3)
c/Å	21.562 (6)
α/°	90
β/°	94.879 (4)
γ/°	90
Volume/Å3	4958 (2)
Z	8
$\rho_{calc}g/cm^3$	1.180
μ/mm^{-1}	0.076
F(000)	1872.0
Crystal size/mm ³	$0.100\times 0.040\times 0.020$
Radiation	MoKa ($\lambda = 0.71073$)
2Θ range for data collection/°	3.604 to 49.99
Index ranges	$\text{-}15 \le h \le 26, \text{-}12 \le k \le 12, \text{-}25 \le l \le 25$
Reflections collected	14327
Independent reflections	4364 [$R_{int} = 0.0386$, $R_{sigma} = 0.0419$]
Data/restraints/parameters	4364/48/300
Goodness-of-fit on F ²	1.009
Final R indexes [I>=2 σ (I)]	$R_1 = 0.0444, wR_2 = 0.0939$
Final R indexes [all data]	$R_1 = 0.0967, wR_2 = 0.1222$
Largest diff. peak/hole / e Å ⁻³	0.14/-0.15

Copies of NMR spectra

¹H NMR spectrum of compound **4b'** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **4b'** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound 5a' (CDCl_3, 400MHz)



 ^{13}C NMR spectrum of compound **5a'** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **5b'** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **5b'** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3a** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3a** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3b** (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound **3b** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound 3c (CDCl_3, 400MHz)



¹³C NMR spectrum of compound **3c** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3d** (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound **3d** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3e** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3e** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3f** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3f** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound **3g** (CDCl_3, 400MHz)



 ^{13}C NMR spectrum of compound **3g** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3h** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3h** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3i**(CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3i** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound 3j (CDCl_3, 400MHz)



¹³C NMR spectrum of compound **3j** (CDCl₃, 100MHz)



¹H NMR spectrum of compound 3k (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound **3k** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3l** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3l** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3m** (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound 3m (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3n** (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound **3n** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **30** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3o** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound **3p** (CDCl_3, 400MHz)



 ^{13}C NMR spectrum of compound **3p** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3q** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3q** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3r** (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound 3r (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3s** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3s** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3t** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3t** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound 3u (CDCl_3, 400MHz)



 ^{13}C NMR spectrum of compound $\boldsymbol{3u}(\text{CDCl}_3, 100\text{MHz})$



¹H NMR spectrum of compound **3v** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3v**(CDCl₃, 100MHz)



¹H NMR spectrum of compound **3w** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3w** (CDCl₃, 100MHz)



HMBC spectrum of compound $\mathbf{3w}$



HMQC spectrum of compound 3w



¹H NMR spectrum of compound **3aa** (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound **3aa** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3ab** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3ab** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3ac** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3ac** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3ad** (CDCl₃, 400MHz)



 ^{13}C NMR spectrum of compound **3ad** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3ae** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3ae** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3af** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3af** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound **3ag** (CDCl_3, 400MHz)



 ^{13}C NMR spectrum of compound **3ag** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3ah** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3ah** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3ai** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3ai** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound **3aj** (CDCl_3, 400MHz)



 ^{13}C NMR spectrum of compound 3aj (CDCl_3, 100MHz)



¹H NMR spectrum of compound **3ak** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3ak** (CDCl₃, 100MHz)



 ^1H NMR spectrum of compound **3al** (CDCl_3, 400MHz)



¹³C NMR spectrum of compound **3al** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3am** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3am** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **3an** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **3an** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **4a** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **4a** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **4b** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **4b** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **5a** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **5a** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **5b** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound **5b** (CDCl₃, 100MHz)



¹H NMR spectrum of compound **9** (CDCl₃, 400MHz)



¹³C NMR spectrum of compound 9 (CDCl₃, 100MHz)



HPLC trace of **3a** HPLC spectrum of racemic compound **3a:** IC column, hexane: *i*-PrOH = 99:1, 0.5 mL/min;



	All and a second second	1.20		- Freed Dr. 4	
#	[min]	[min] [mAU*s]	[mAU]	%	
	-				N ₃ O
1	14.835 BV	0.6256 3.29110e4	736.17560	50.2739	Ph
2	2 16.829 VB	0.6449 3.25525e4	718.07111	49.7261	3a
34		0 5400		070	
No.	重 :	6. 5463	be4 1454.24	:670	

HPLC spectrum of chiral compound **3a**, minor enantiomer t = 16.3 min, major enantiomer t = 14.4 min.)



HPLC spectrum of racemic compound 3d (IC column, hexane: i-PrOH = 99:1, 0.5 mL/min)



HPLC spectrum of chiral compound 3d (IC column, hexane: i-PrOH = 99:1, 0.5 mL/min)



9. References

1. Chatalova-Sazepi, C., Wang, Q., Sammis, G. M., Zhu, J. Copper-Catalyzed Intermolecular Carboetherification of Unactivated Alkenes by Alkyl Nitriles and Alcohols. *Angew. Chem. Int. Ed.* **54**, 5443–5446 (2015).

2. Nimse, S. B., Pal, D., Mazumder, A., Mazumder, R. Synthesis of Cinnamanilide Derivatives and Their Antioxidant and Antimicrobial Activity. *Journal of Chemistry*. **2015**, Article ID 208910, 5 pages.

3. Sanchez-Moreno, C. Review: Methods Used to Evaluate the Free Radical Scavenging Activity in Foods and Biological Systems. *Food Science and Technology International* **8**, 121–137 (2002).

4. Wang, T.-C., Chen, Y.-L., Lee, K.-H., Tzeng, C.-C. Lewis Acid Catalyzed Reaction of Cinnamanilides: Competition of Intramolecular and Intermolecular Friedel-Crafts Reaction. *Synthesis* **1997**, *1*, 87–90 (1997).

5. Furuya, T., Strom, A. E., Ritter, T. Silver-Mediated Fluorination of Functionalized Aryl Stannanes. J. Am. Chem. Soc. **131**, 1662–1663 (2009).

6. Straathof, N. J. W., Cramer, S. E., Hessel, V., Noel, T., *Practical Photocatalytic Trifluoromethylation and Hydrotrifluoromethylation of Styrenes in Batch and Flow. Angew. Chem. Int. Ed.* **55**, 15549–15553 (2016).

7. Liao, S., List, B. Asymmetric Counteranion-Directed Transition-Metal Catalysis: Enantioselective Epoxidation of Alkenes with Manganese(III) Salen Phosphate Complexes. *Angew. Chem. Int. Ed.* **49**, 628–631 (2010).

8. Xi, X., Shao, J., Hu, X., Wu, Y. Structure and asymmetric epoxidation reactivity of chiral Mn(III) salen catalysts modified by different axial anions. *RSC Adv.* **5**, 80772–80778 (2015).

9. Lee, K. N., Lei, Z., Ngai, M.-Y. β -Selective Reductive Coupling of Alkenylpyridines with Aldehydes and Imines via Synergistic Lewis Acid/Photoredox Catalysis. *J. Am. Chem. Soc.* **139**, 5003–5006 (2017).

10. Nandy, J. P., Prabhakaran, E. N., Kumar, S. K., Kunwar, A. C., Iqbal, J. Reverse Turn Induced π -Facial Selectivity during Polyaniline-Supported Cobalt(II) Salen Catalyzed Aerobic Epoxidation of N-Cinnamoyl l-Proline Derived Peptides. *J. Org. Chem.* **68**, 1679–1692 (2003).

11. Zhang, H.-B., Wang, Y., Gu, Y., Xu, P.-F. Lewis- and Brønsted -acid cooperative catalytic radical coupling of aldehydes and azodicarboxylate. *RSC Adv.* **4**, 27796–27799 (2014).